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Navneet S. Majhail,1,2 J. Douglas Rizzo,3 Stephanie J. Lee,4 Mahmoud Aljurf,5
Yoshiko Atsuta,6 Carmem Bonfim,7 Linda J. Burns,8 Naeem Chaudhri,5 Stella Davies,9
Shinichiro Okamoto,10 Adriana Seber,11 Gerard Socie,12 Jeff Szer,13 Maria Teresa Van Lint,14
John R. Wingard,15 Andre Tichelli16 for the Center for International Blood and Marrow
Transplant Research (CIBMTR), American Society for Blood and Marrow Transplantation
(ASBMT), European Group for Blood and Marrow Transplantation (EBMT), Asia-Pacific Blood
and Marrow Transplantation Group (APBMT), Bone Marrow Transplant Society of Australia
and New Zealand (BMTSANZ), East Mediterranean Blood and Marrow Transplantation
Group (EMBMT), and Sociedade Brasileira de Transplante de Medula Ossea (SBTMO)Advances in hematopoietic cell transplantation (HCT) technology and supportive care techniques have led to
improvements in long-term survival after HCT. Emerging indications for transplantation, introduction of
newer graft sources (eg, umbilical cord blood) and transplantation of older patients using less intense con-
ditioning regimens have also contributed to an increase in the number of HCT survivors. These survivors are
at risk for developing late complications secondary to pre-, peri-, and posttransplantation exposures and risk
factors. Guidelines for screening and preventive practices for HCT survivors were published in 2006. An in-
ternational group of transplantation experts was convened in 2011 to review contemporary literature and
update the recommendations while considering the changing practice of transplantation and international
applicability of these guidelines. This review provides the updated recommendations for screening and pre-
ventive practices for pediatric and adult survivors of autologous and allogeneic HCT.
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Approximately 50,000 people undergo hematopoi-
etic cell transplantation (HCT) worldwide each year.
Advances in transplantation techniques and supportive
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Biol Blood Marrow Transplant 18:348-371, 2012 349Late Effects Guidelines for HCT Survivorsexpectancy of HCT survivors is lower than expected at
10 to 30 years posttransplantation and secondary can-
cers, infections, and organ dysfunction are common
causes of late deaths in this population [1-6].
Recognizing the need for guidance about appro-
priate systematic long-term follow-up of HCT survi-
vors, the Center for International Blood and Marrow
Transplant Research (CIBMTR), the European
Group for Blood and Marrow Transplantation, and
the American Society for Blood and Marrow Trans-
plantation convened a group of experts in 2006 and
provided consensus recommendations for screening
and preventive practices for autologous and allogeneic
HCT survivors [7,8]. To update these previous
guidelines, the international working group was
reconvened in 2011 to review the prevailing
literature in late effects of transplantation and to
suggest revised guidelines, if applicable. To ensure
international applicability, the working group
included participants from the Asia-Pacific Blood
and Marrow Transplantation Group, the Bone Mar-
row Transplant Society of Australia and New Zealand,
the East Mediterranean Blood and Marrow Trans-
plantation Group, and Sociedade Brasileira de Trans-
plante de Medula Ossea.
The proposed guidelines focus on risks faced by
children and adults who have survived 6 months or
more following transplantation and address autolo-
gous and allogeneic HCT recipients. Since long-
term HCT recipients may no longer be under the
care of transplant centers and may have returned to
the care of community health care providers, the
guidelines are geared towards providers who routinely
care for HCT recipients as well as those who do not.
The working group recognized the general lack of
clinical trials focused on screening and preventive
practices among HCT recipients and the need for
more research in this area. Hence, many of these rec-
ommendations are not based on evidence derived
from randomized or other controlled trials but are
supported by retrospective studies that have identified
specific complications in long-term survivors and their
associated risk-factors. When such studies are not
available, the guidelines are based on knowledge de-
rived from non-transplant patients as well as on the
consensus opinion of the working group participants.
Taking into account the risks and potential conse-
quences of late complications, they represent sensible
practices to optimize outcomes. The recommenda-
tions should not be interpreted as mandatory for all re-
cipients; good medical practice and judgment dictate
that certain recommendations may not be applicable
or may even be contraindicated in individual patients
or groups of patients.
It was also recognized that the practice of HCT is
continuously changing. Some examples of suchchanges include emerging indications for transplanta-
tion (e.g. autoimmune diseases, sickle cell disease), in-
creased utilization of newer donor sources (e.g.
umbilical cord blood and haploidentical donors), de-
creased use of total body irradiation (TBI) for condi-
tioning and evaluation of novel therapies as part of
HCT (e.g. post-transplant maintenance therapy in
myeloma). With the advent of non-myeloablative
and reduced intensity conditioning (NMA/RIC) regi-
mens, a larger number of older patients now receive
transplantation. The risks and constellation of late
complications may change as newer practices in trans-
plantation become more prevalent. Providers should
be cognizant of any unique exposures and risks associ-
ated with these practices (e.g. delayed immune recon-
stitution in umbilical cord blood recipients) when
considering a long-term followup care plan for their
patients.
A broad constellation of medical issues faced by
late survivors of transplantation is presented. Most of
the late complications discussed here pertain particu-
larly to allogeneic recipients. However, autologous re-
cipients are at risk for many of the same late
complications and may experience unusual toxicity or
immune impairment following transplantation that
places them at risk similar to allogeneic recipients
(e.g. exposure to prolonged corticosteroids or other
drugs that may cause prolonged lymphopenia post-
transplantation). Therefore, although some of the
following recommendations do not generally apply
to autologous recipients, providers should remain alert
to these complications in all patients.
The guidelines are summarized in Tables 1 and 2.
The Supplementary Tables includes tables that
highlight recommendations for post-transplant immu-
nizations (Appendix Table A) and recommendations
by selected exposures/risk-factors (TBI, chronic
GVHD, pediatric recipients) (Appendix Table B).
Appendix Table C lists other guidelines that have
been referenced in this manuscript along with current
links to their website. Readers can also refer to guide-
lines developed by the Children’s Oncology Group
for followup for pediatric cancer survivors, which in-
clude information on pediatric HCT recipients (www.
survivorshipguidelines.org). Representative references
are included in this document to guide readers who
would like more information on individual topics.
The National Marrow Donor Program (NMDP)
publishes a patient version of the followup guidelines
(www.BeTheMatch.org/Patient); we recommend that
patients use these guidelines to establish a long-term
followup care plan in consultation with their health
care provider based on their individual exposures and
risk factors. The NMDP also makes a summary of
the guidelines available for physicians, (online, mobile
app, and in print at www.marrow.org/md-guidelines).
Table 1. Summary Recommendations for Screening and Prevention of Late Complications in Long-Term HCT Survivors
Tissues/Organs Late Complications General Risk Factors Monitoring Tests
Monitoring Tests and Preventive
Measures on All HCT Recipients
Monitoring Tests and Preventive Measures in
Special Populations
Immune system -Infections -Donor source
-HLA disparity
-T cell depletion
-GVHD
-Prolonged immunosuppression
-Venous access devices
-CMV antigen or PCR in patients
at high risk for CMV
reactivation
-PCP prophylaxis for initial 6 months after HCT
-Immunizations posttransplantation according
to published guidelines
-Administration of antibiotics for endocarditis
prophylaxis according to American Heart
Association guidelines
-Patients with cGVHD: Antimicrobial
prophylaxis targeting encapsulated organisms
and PCP for the duration of
immunosuppressive therapy
-Patients with cGVHD: Screening for CMV
reactivation should be based on risk factors,
including intensity of immunosuppression.
Ocular -Cataracts
-Sicca syndrome
-Microvascular retinopathy
-TBI/radiation exposure to head
and neck
-Corticosteroids
-GVHD
-Ophthalmologic exam -Routine clinical evaluation at 6 months and 1
year after HCTand at least yearly thereafter
-Ophthalmologic examination with
measurement of visual acuity and fundus
examination at 1 year after HCT, subsequent
evaluation based on findings and risk factors
-Prompt ophthalmologic examination in patients
with visual symptoms
-Patients with cGVHD: Routine clinical
evaluation, and if indicated, ophthalmologic
examination more frequently
Oral -Sicca syndrome
-Caries
-GVHD
-TBI/radiation exposure to head
and neck
-Dental assessment -Education about preventive oral health
practices
-Clinical oral assessment at 6 months and 1 year
after HCT and at least yearly thereafter with
particular attention to intraoral malignancy
evaluation
-Dental assessment at 1 year after HCTand then
at least yearly thereafter
-Pediatric recipients: Yearly assessment of teeth
development
-Patients with cGVHD: Consider more frequent
oral and dental assesments with particular
attention to intraoral malignancy evaluation
Respiratory -Idiopathic pneumonia
syndrome
-Bronchiolitis obliterans
syndrome
-Cryptogenic organizing
pneumonia
-Sinopulmonary infections
-TBI/radiation exposure to
chest
-GVHD
-Infectious agents
-Allogeneic HCT
-Busulfan exposure
-PFTs
-Radiologic studies
(eg, chest x-ray, CT scan)
-Routine clinical evaluation at 6 months and
1 year after HCTand at least yearly thereafter
-Assessment of tobacco use and couselling
against smoking
-PFTs and focused radiologic assessment for
allogeneic HCT recipients with symptoms or
signs of lung compromise
-Patients with cGVHD: Some experts
recommend earlier and more frequent clinical
evaluation and PFTs
Cardiac and vascular -Cardiomyopathy
-Congestive heart failure
-Arrhythmias
-Valvular anomaly
-Coronary artery disease
-Cerebrovascular disease
-Peripheral arterial disease
-Anthracycline exposure
-TBI/radiation exposure to neck
or chest
-Older age at HCT
-Allogeneic HCT
-Cardiovascular risk factors
before/after HCT
-Chronic kidney disease
-Metabolic syndrome
-Cumulative dose of anthracyclines
-Echocardiogram with ventricular
function, ECG in patients at
risk and in symptomatic patients
-Fasting lipid profile (including
HDL-C, LDL-C and triglycerides)
-Fasting blood sugar
-Routine clinical assessment of cardiovascular
risk factors as per general health maintenance
at 1 year and at least yearly thereafter
-Education and counseling on ‘‘heart-healthy’’
lifestyle (regular exercise, healthy weight, no
smoking, dietary counseling)
-Early treatment of cardiovascular risk factors
such as diabetes, hypertension, and
dyslipidemia
-Administration of antibiotics for endocarditis
prophylaxis according to American Heart
Association guidelines
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Liver -GVHD
-Hepatitis B
-Hepatitis C
-Iron overload
-Cumulative transfusion
exposure
-Risk factors for viral
hepatitis transmission
-LFTs
-Liver biopsy
-Serum ferritin
-Imaging for iron overload
(MRI or SQUID)
-LFTs every 3-6 months in the first year, then
individualized, but at least yearly thereafter
-Monitor viral load by PCR for patients
with known hepatitis B or C, with liver
and infectious disease specialist consultation
-Consider liver biopsy at 8-10 years after HCT
to assess cirrhosis in patients with chronic
HCV infection
-Serum ferritin at 1 year after HCT in patients
who have received RBC transfusions;
consider liver biopsy or imaging study for
abnormal results based on magnitude of
elevation and clinical context; subsequent
monitoring is suggested for patients with
elevated LFTs, continued RBC transfusions,
or presence of HCV infection
Renal and genitourinary -Chronic kidney disease
-Bladder dysfunction
-Urinary tract infections
-TBI
-Drug exposure (eg, calcineurin
inhibitors, amphotericin,
aminoglycosides)
-CMV
-Hemorrhagic cystitis
-Urine protein
-Serum creatinine
-BUN
-Blood pressure assessment at every clinic visit,
with aggressive hypertension management
-Assess renal function with BUN, creatinine
and urine protein at 6 months, 1 year and
at least yearly thereafter
-Consider further workup (kidney biopsy or
renal ultrasound) for for further workup of
renal dysfunction as clinically indicated
Muscle and connective
tissue
-Myopathy
-Fascitis/scleroderma
-Polymyositis
-Corticosteroids
-GVHD
-Evaluate ability to stand from
a sitting position
-Clinical evaluation of joint range of
motion
-Follow general population guidelines for
physical activity
-Frequent clinical evaluation for myopathy in
patients on corticosteroids
-Patients with cGVHD: Physical therapy
consultation in patients with prolonged
corticosteroid exposure, fascitis, or
scleroderma
-Patients with cGVHD: Frequent clinical
evaluation by manual muscle tests or by
assessing ability to go from sitting to standing
position for patients on prolonged
corticosteroids
Skeletal -Osteopenia/
osteoporosis
-Avascular necrosis
-Inactivity
-TBI
-Corticosteroids
-GVHD
-Hypogonadism
-Allogeneic HCT
-Dual photon densitometry
-MRI to evaluate patients
with joint symptoms
-Dual photon densitometry at 1 year for adult
women, all allogeneic HCTrecipients and
patients who are at high risk for bone loss;
subsequent testing determined by defects or
to assess response to therapy
-Physical activity, vitamin D, and calcium
supplementation to prevent loss of bone
density
-Patients with cGVHD: Consider dual photon
densitometry at an earlier date in patients
with prolonged corticosteroid or calcineurin
inhibitor exposure.
Nervous system -Leukoencephalopathy
-Late infections
-Neuropsychological and
cognitive deficits
-Calcineurin neurotoxicity
-Peripheral neuropathy
-TBI/radiation exposure
to head
-GVHD
-Exposure to
fludarabine
-Intrathecal chemotherapy
- -Clinical evaluation for symptoms and signs of
neurologic dysfunction at 1 year and yearly
thereafter
-Diagnostic testing (eg, radiographs, nerve
conduction studies) for those with symptoms
or signs
-Pediatric recipients: Annual assessment for
congnitive development milestones
(Continued)
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Table 1. (Continued)
Tissues/Organs Late Complications General Risk Factors Monitoring Tests
Monitoring Tests and Preventive
Measures on All HCT Recipients
Monitoring Tests and Preventive Measures in
Special Populations
Endocrine -Hypothyroidism
-Hypoadrenalism
-Hypogonadism
-Growth retardation
-TBI/radiation exposure
(eg, head and neck, CNS)
-Corticosteroids
-Young age at HCT
-Chemotherapy exposure
-Thyroid function tests
-FSH, LH, testosterone
-Growth velocity in children
-Thyroid function testing yearly post-HCT, or if
relevant symptoms develop
-Clinical and endocrinologic gonadal assessment
for postpubertal women at 1 year,
subsequent follow-up based on menopausal
status
-Gonadal function in men, including FSH, LH,
and testosterone, should be assessed as
warranted by symptoms
-Pediatric recipients: Clinical and endocrinologic
gonadal assessment for prepubertal boys and
girls within 1 year of transplantation, with
further follow-up as determined in
consultation with a pediatric endocrinologist
-Pediatric recipients: Monitor growth velocity in
children annually; assessment of thyroid and
growth hormone function if clinically
indicated
-Patients with cGVHD: Slow terminal tapering
of corticosteroids for those with prolonged
exposure
-Patients with cGVHD: Consider stress doses of
corticosteroids during acute illness for
patients who have received chronic
corticosteroids
Mucocutaneous -Cutaneous sclerosis
-Genital GVHD
-GVHD
-TBI/radiation exposure
to pelvis
-Pelvic exam -Counsel patients to perform routine self-exam
of skin and avoid excessive exposure to
sunlight without adequate protection
-Annual gynecologic exam in women to detect
early involvement of vaginal mucosa byGVHD
-Patients with cGVHD and TBI recipients:
Consider more frequent gynecologic
evaluation based on clinical symptoms
Second cancers -Solid tumors
-Hematologic malignancies
-PTLD
-GVHD
-TBI/radiation exposure
-T cell depletion
-Exposure to alkylating agents or
etoposide
-Mammogram
-Screening for colon cancer
(eg, colonscopy, sigmoidoscopy,
fecal occult blood testing)
-Pap smear
-Counsel patients about risks of secondary
malignancies annually and encourage them to
perform self-exam (eg, skin, testicles/genitalia)
-Counsel patients to avoid high-risk behaviors
(eg, smoking)
-Follow general population recommendations
for cancer screening
-Patients with cGVHD: Clinical and dental
evaluation with particular attention toward
oral and pharyngeal cancer
-TBI and chest irradiation recipients: Screening
mammography in women starting at age 25 or
8 years after radiation exposure, whichever
occurs later but no later than age 40
Psychosocial and sexual -Depression
-Anxiety
-Fatigue
-Sexual dysfunction
-Prior psychiatric morbidity
-Hypogonadism
-Psychological evaluation -Clinical assessment throughout recovery
period, at 6 months, 1 year, and annually
thereafter, with mental health professional
counseling recommended for those with
recognized deficits
-Encouragement of robust support networks
-Regularly assess level of spousal/caregiver
psychological adjustment and family
functioning
-Query adults about sexual function at 6
months, 1 year, and at least annually thereafter
Fertility -Infertility -TBI/radiation exposure
-Chemotherapy exposure
-FSH, LH levels -Consider referral to appropriate specialists for
patients who are contemplating a pregnancy
or are having difficulty conceiving
-Counsel sexually active patients in the
reproductive age group about birth control
post-HCT
General health -Recommended screening as per general
population (see text)
PCR, polymerase chain reaction; PCP, Pneumocystis pneumonia; CT, computed tomography; ECG, electrocardiogram; BUN, blood urea nitrogen; CNS, central nervous system; FSH, follicle-stimulating hormone; LH,
luteinizing hormone.
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Table 2. Abbreviated Summary Recommendations for
Screening and Prevention of LateComplications in Long-Term
HCT Survivors Organized by Time after Transplantation
Recommended Screening/Prevention 6 Months 1 Year Annually
Immunity
Encapsulated organism prophylaxis 2 2 2
PCP prophylaxis 1 2 2
CMV testing 2 2 2
Immunizations 1 1 1
Ocular
Ocular clinical symptom evaluation 1 1 1
Ocular fundus exam + 1 +
Oral complications
Clinical assessment 1 1 1
Dental assessment + 1 1
Respiratory
Clinical pulmonary assessment 1 1 1
Smoking tobacco avoidance 1 1 1
Pulmonary function testing + + +
Chest radiography + + +
Cardiac and vascular
Cardiovascular risk-factor assessment + 1 1
Liver
Liver function testing 1 1 +
Serum ferritin testing 1 +
Kidney
Blood pressure screening 1 1 1
Urine protein screening 1 1 1
BUN/creatinine testing 1 1 1
Muscle and connective tissue
Evaluation for muscle weakness 2 2 2
Physical activity counseling 1 1 1
Skeletal
Bone density testing (adult women, all
allogeneic transplantation recipients and
patients at high risk for bone loss)
1 +
Nervous system
Neurologic clinical evaluation + 1 1
Evaluate for cognitive development 1 1
Endocrine
Thyroid function testing 1 1
Growth velocity in children 1 1
Gonadal function assessment
(prepubertal men and women)
1 1 1
Gonadal function assessment
(postpubertal women)
1 +
Gonadal function assessment
(postpubertal men)
+ +
Mucocutaneous
Skin self-exam and sun exposure counseling 1 1 1
Gynecologic exam in women + 1 1
Second cancers
Second cancer vigilance counseling 1 1
Screening for second cancers 1 1
Psychosocial
Psychosocial/QOL clinical assessment 1 1 1
Sexual function assessment 1 1 1
15 recommended for all transplantation recipients; 25 recommended
for any patient with ongoing cGVHD or immunosuppression; +5 reas-
sessment recommended for abnormal testing in a previous time period
or for new signs/symptoms.
Biol Blood Marrow Transplant 18:348-371, 2012 353Late Effects Guidelines for HCT SurvivorsIMMUNITYAND INFECTIONS
International consensus guidelines for preventing
infectious complications among HCT recipients
were published in 2009; these guidelines compre-
hensively address late infectious complications of
transplantation and provide recommendations for vac-
cination of HCT recipients [9-11]. Environmentalrisks, safe sex, water and food safety, and travel safety
among HCT recipients have also been covered
by these guidelines. Patients who are immune
compromised should be educated regarding their
immune status and of the warning symptoms of
infection and advised to seek early medical attention
if they have symptoms.
Infectious complications are frequent in the period
soon after HCT because of cytopenias, immune abla-
tion, and/or immunosuppression. Immune reconst-
itution occurs gradually over time (generally 12-18
months) and is slower for allogeneic recipients, partic-
ularly those receiving umbilical cord blood, HLA-
mismatched or T cell-depleted grafts and in survivors
with GVHD or those who have received prolonged
immunosuppression [12]. T-helper lymphocyte
(CD4) counts and CD4/CD8 ratios are good markers
of immune reconstitution, and some experts use these
assessments as surrogate markers of the completeness
of immune reconstitution to guide duration of viral
or other infection prophylaxis after HCT.
Bacterial, fungal, and viral infections may occur
months or years after transplantation in patients with
delayed immune reconstitution. Although infectious
risk is highest in the first 1 to 2 years after transplanta-
tion, an increased risk of infection may continue long
term for some recipients of allogeneic transplanta-
tions, such as patients with cGVHD requiring ex-
tended immunosuppressive therapy. In patients with
cGVHD, opsonization is impaired, and encapsulated
bacteria (N. meningitides, H. influenzae, and S. pneumo-
nia) may cause rapidly progressive and life-threatening
infection. Furthermore, patients may have undergone
splenectomy for the treatment of their underlying dis-
ease or may be functionally asplenic secondary to
GVHD or splenic irradiation. Although patients with
asplenia are at increased risk of infections, recommen-
dations regarding antibiotic prophylaxis are inconsis-
tent. Patients with combined risk of asplenia and
immunosuppression for GVHD should receive antibi-
otic prophylaxis as recommended in the information to
follow. Otherwise, patients with asplenia should, at
a minimum, be warned regarding the need for prompt
medical attention for febrile illnesses.
Aspergillus infection of the lungs or sinuses is the
most commonly described late fungal infection, al-
though Candida and Mucor species are late pathogens
seen infrequently. Late-onset cytomegalovirus
(CMV) reactivation and infection has been reported
more frequently in recent years with the increasing
use of prophylactic or preemptive antiviral drugs in
the early post-HCT period. Late CMV infections
are most commonly seen in patients treated for early
CMV infection or in those with cGVHD or late im-
mune manipulation (eg, donor lymphocyte infusion
recipients). Varicella zoster virus (VZV) infection fre-
quently occurs in the first year after transplantation,
354 Biol Blood Marrow Transplant 18:348-371, 2012N. S. Majhail et al.especially in patients with cGVHD. In patients receiv-
ing prophylaxis against herpes virus infections, VZV
reactivation is most commonly seen in the 2 to 3
months after cessation of prophylaxis. Acyclovir pro-
phylaxis is recommended for 1-year posttransplanta-
tion for both autologous and allogeneic recipients at
risk for VZV disease; prophylaxis may be continued
beyond 1 year among patients who have cGVHD or
require systemic immune suppression. Recurrent her-
pes simplex virus infections can occasionally occur in
patients with cGVHD.
Although Pneumocystis jirovecii (previously Pneumo-
cystis carinii) pneumonia (PCP) generally occurs during
the first 6 months after HCT, patients are at risk for as
long as immunosuppressive therapy is given for
cGVHD. Autologous HCT recipients are also at risk
of PCP, particularly during the first 6 months; the
risk may be substantial if there has been prolonged
corticosteroid exposure before or after transplantation
and in patients who have received intensive condi-
tioning.
Sinusitis is an occasional complication, especially
after allogeneic HCT and is more frequent in patients
with low immunoglobulin levels. Sinus pathogens are
rarely identified because invasive diagnostic proce-
dures are not frequently performed. Exposure to
calcineurin inhibitors that can induce mucosal hyp-
ertrophy and mucosal involvement by cGVHD can
increase the risk of secondary sinus infections with
bacteria or molds.
Supplemental intravenous immune globulin is
sometimes recommended for patients with severe in-
fections and IgG levels below 400 mg/dL (4 g/L),
and infusions are continued until infection has abated
[9,10]. The use of prophylactic intravenous immune
globulin in HCT patients in the absence of infection
remains controversial.
Transplantation recipients who reside in certain
geographic areas may be susceptible to locally preva-
lent infections (eg, tuberculosis, malaria, Chagas dis-
ease, leishmaniasis). Healthcare providers taking care
of such patients should be aware of guidelines for the
prevention and management of such infections
[10,13,14].
Recommendations
1. Patients with cGVHD should receive antibiotic
prophylaxis targeting encapsulated organisms given
for at least as long as immunosuppressive therapy is
administered.
2. Antiviral and antifungal prophylaxis should be con-
sidered in patients at high risk for viral and fungal
infections (eg, patients with cGVHD) according
to published guidelines [9,10]. Screening for
CMV reactivation should be based on risk factors,
including intensity of immunosuppression.3. Administration of prophylactic antibiotics for oral
procedures should follow the American Heart As-
sociation guidelines for endocarditis prophylaxis
[15]. Some experts recommend antibiotic prophy-
laxis before dental care in patients on immunosup-
pressive therapy for cGVHD and in patients with
indwelling central venous catheters.
4. Allogeneic HCT recipients should receive PCP
prophylaxis from engraftment until at least 6
months after transplantation or as long as immuno-
suppressive therapy is given (eg, for the treatment
or prevention of cGVHD). PCP prophylaxis for 3
to 6 months posttransplantation should be con-
sidered for autologous HCT recipients with
substantial immunosuppression (eg, patients with
lymphoma, leukemia, or myeloma, especially
when pretransplantation treatments or condition-
ing regimens have included purine analogues or
high-dose corticosteroids).
5. Immunization with inactivated vaccines for all
patients according to published guidelines
(Appendix Table A) [9-11]. Because patients with
cGVHD can mount responses to vaccines and are
at risk for infections, postponing vaccination in
patients with GVHD is not recommended with
the exception of live vaccines. When vaccinating
patients with active GVHD, it may be prudent to
measure specific antibody levels before and after
vaccination, to determine their level of protection
and need for booster immunizations.OCULAR COMPLICATIONS
There are threemain ocular late effects afterHCT.
Anterior segment ocular complications of keratocon-
junctivitis sicca syndrome and cataracts are well de-
scribed. Ischemic microvascular retinopathy is
a posterior segment complication that is being increas-
ingly recognized and appears to be related to radiation
exposure.
Ocular sicca syndrome is usually part of a more
general sicca syndrome with xerostomia, vaginitis,
and dryness of skin and is associated with cGVHD
[16]. Ocular manifestations include reduced tear
flow, keratoconjunctivitis sicca, sterile conjunctivitis,
corneal epithelial defects, and corneal ulceration.
Symptoms include burning, irritation, pain, foreign
body sensation, blurred vision, photophobia, and par-
adoxically, excessive tearing. The diagnosis of kerato-
conjunctivitis sicca is made by the presence of
appropriate symptoms, evidence of decreased tear pro-
duction on Schirmer’s test, and clinical signs of kerati-
tis. In all cases, infectious keratitis must be ruled out.
The incidence is approximately 40% to 60% in pa-
tients with cGVHD [17]. Artificial tears can provide
symptomatic treatment of dry eye. Information
Biol Blood Marrow Transplant 18:348-371, 2012 355Late Effects Guidelines for HCT Survivorsregarding frequency of use of artificial tear drops can
indicate severity of dry eye syndrome. Treatment in-
cludes systemic treatment of cGVHD and topical
treatment to increase lubrication, control evaporation
or drainage, and decrease ocular surface inflammation
[18]. Temporary or permanent occlusion of the tear
duct puncta for drainage control may provide benefit.
In general, contact lens usage is discouraged in patients
with keratoconjunctivitis sicca because of an increased
risk of abrasion; however, some lenses such as scleral
lensesmay be beneficial in severe cases to control evap-
oration. Such an approach should occur only with the
close supervision of an ophthalmologist. Topical corti-
costeroids or calcineurin inhibitors may improve
symptoms but can cause sight-threatening compl-
ications when inappropriately used in herpes simplex
virus or bacterial keratitis.Ocular surface inflammation
may be decreased with autologous serum, but this
treatment is available in a limited number of centers.
Cataract formation occurs frequently after TBI
exposure. After myeloablative single-dose TBI, almost
all patients develop cataracts within 3 to 4 years. Frac-
tionation ofTBI delays onset and reduces the incidence
of cataract to 40% to 70% at 10 years
posttransplantation [19,20]. In patients conditioned
without TBI, the probability of cataract formation at
10 years is 5% to 20% [20,21]. Other risk factors for
cataract formation after HCT are older age, use
of corticosteroids, and allogeneic compared with
autologous transplantation. Approximately 45% of
recipients treated with corticosteroids for
a prolonged period of time develop cataracts at 10
years. In the near future, the overall cumulative
incidence of cataracts after HCT is expected to
decrease as fewer patients receive TBI-based condi-
tioning. Cataracts are effectively treated surgically.
Cataract extraction can be performed safely even
when ocular sicca is present. Surgery is indicated if
vision is impaired and the impairment is interfering
with daily life.
Patients with ischemic microvascular retinopathy
present with cotton wool spots and optic disc edema.
Retinopathy is observed almost exclusively after allo-
geneic transplantation, particularly in patients condi-
tioned with TBI and in patients receiving
cyclosporine for GVHD prophylaxis. In most cases,
retinal lesions resolve with withdrawal or reduction
of immunosuppressive therapy, even in cases where vi-
sual acuity is decreased. Other ocular complications in
the posterior segment include hemorrhage, optic disc
edema, and infectious retinitis (eg, from herpes viruses
including CMV, toxoplasma, and fungi).
Recommendations
1. Routine clinical evaluation of visual history and
symptoms, with attention to sicca syndrome, is rec-ommended at 6 months, 1 year, and yearly thereaf-
ter for all HCT recipients.
2. Referral to an expert in ophthalmology for routine
ocular examination with measurement of visual
acuity and fundus examination at 1 year after
transplantation is recommended for all HCT recip-
ients. Patients with cGVHDmay be referred for an
ophthalmologic exam sooner than 1 year posttrans-
plantation. Subsequent frequency of routine
screening should be individualized according to
recognized defects, ocular symptoms, or the pres-
ence of cGVHD.
3. Patients experiencing visual symptoms should
undergo ocular examination immediately.ORAL COMPLICATIONS
Late complications involving the oral cavity are
common after HCT. The most important risk factors
for oral late effects are oral cGVHD, the use and dose
of irradiation to head and neck region, underlying di-
agnosis of Fanconi’s anemia, and the age of the patient
at HCT. Pretransplantation evaluation should include
clinical assessment of oral health status to serve as
a baseline for monitoring posttransplantation oral
complications.
The mouth is one of the most frequently affected
organs in cGVHD [22,23]. The oral changes
involving the oral mucosa, salivary glands, oral and
lingual muscles, taste buds, and gingiva may
completely regress, but some long-term sequela may
continue despite the resolution of cGVHD. Patients
often report oral pain, dryness, odynophagia, dyspha-
gia, and sensitivity (irritation from normally tolerated
spices, foods, liquids, or flavors) that may limit oral in-
take. The presence of lichen planus, hyperkeratotic
plaques, and restriction of mouth opening by perioral
fasciitis or skin sclerosis are diagnostic signs of oral
GVHD. Patients may also have mucosal erythema, at-
rophy, oral dryness, mucoceles (because of inflamma-
tion and obstruction of the salivary gland ducts),
pseudomembranes, and ulcers. Salivary gland dysfunc-
tion and xerostomia increase the risk of dental caries,
periodontal disease, and oral cancer [22,24]. Patients
with GVHD can be treated with topical oral
steroids, systemic treatments for GVHD, and
supportive care for xerostomia symptoms as outlined
in the information to follow.
Even in patients who have never had GVHD,
some degree of salivary gland hypofunction may per-
sist for prolonged periods of time after receiving che-
motherapy and especially after local irradiation. Oral
dryness is also a side effect of commonly used medica-
tions (eg, antidepressants, antihistamines, diuretics,
muscle relaxants, and some analgesics). Medication
lists should be reviewed to identify and eliminate any
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pending on the severity of xerostomia, patients may
complain of oral sensitivity, abnormal taste, and may
feel a constant sore throat, or have problems speaking
and swallowing. The decrease in salivation predis-
poses patients to dental decay, oral infections (eg, her-
pes simplex and oral candidiasis), mechanical and
epithelial injuries, and impairs remineralization of
teeth. Xerostomia can be difficult to manage. Symp-
tom relief can be achieved with artificial saliva and
oral rinses; sugar-free candies or gum can stimulate
the saliva flow. Sialogogues (eg, pilocarpine, cevime-
line) may be tried in adults. Frequent sipping of water
may help decrease symptoms and especially help
chewing and swallowing food. Patients with xerosto-
mia should receive meticulous oral hygiene, undertake
preventive measures for dental and periodontal
disease, and aggressive treatment of oral infections.
Further trauma to the oral mucosa should be avoided,
and mouth guards may be used, if necessary. Oral
piercing should be avoided.
Squamous cell oral cancer can arise from the buc-
cal mucosa, salivary glands, gingiva, lip, or tongue (see
section on Secondary Cancers) [24-26]. Patients with
a history of oral cGVHD and patients with Fanconi’s
anemia are particularly at risk and must be carefully
screened throughout their lives. Frequent self- and
professional oral examination is the mainstay for
early diagnosis of oral cancer. Patients should be
vigilant for and report lesions that do not heal,
leukoplakia, localized pain, and changes in color or
texture of the mucosa. Patients with Fanconi’s
anemia should be examined every 6 months, and oral
examination should be part of the standard annual
examination of all other HCT patients.
Children undergoing HCT may have damage to
the enamel layer, and the teeth may have discolored
patches or stain easily. Depending on the child’s age,
permanent teeth may start developing again within
a few months of transplantation. Normal dental devel-
opment may be altered in 50% to 80% of children be-
cause of prior therapies or conditioning regimen
exposure [27]. Tooth agenesis, hypodontia, microdon-
tia of the crowns of erupted permanent teeth, narrow-
ing of the pulp canal, thinning and tapering of the roots
of erupted permanent molars or incisors, delayed erup-
tion, and primary tooth retention have been described
andmay jeopardize occlusal development. After irradi-
ation, underdevelopment of the mandible and anoma-
lies in the mandibular joint may also occur. Young age
atHCT and exposure to TBI are important risk factors
for problems with dental development.
Among HCT recipients who require dental proce-
dures, the American Heart Association recomm-
endations for antimicrobial prophylaxis against
endocarditis should be followed (see section on Immu-
nity and Infections) [15].Recommendations
1. All HCT recipients should be educated about pre-
ventive oral health and routine dental maintenance.
Patients should also be counseled to avoid smoking
and chewing tobacco, decrease regular intake of
sugar containing beverages, and avoid intraoral
piercing.
2. Clinical oral evaluations should be performed at 6
months, 1 year, and yearly thereafter. More fre-
quent evaluations may be needed in patients at
high risk of oral complications (eg, cGVHD, expo-
sure to TBI). Monitoring of oral complications
posttransplantation is facilitated by thorough pre-
HCT baseline oral assessment.
3. Patients at high risk for squamous cell cancers of the
oral cavity (eg, oral cGVHD, Fanconi’s anemia)
should undergo clinical oral evaluations every 6
months and should be educated to maintain metic-
ulous oral hygiene and taught oral self-inspection.
4. All HCT recipients should receive a thorough eval-
uation by a dentist or oral medicine specialist at 1
year after HCT and yearly thereafter. More fre-
quent dental consultationsmay be considered in pa-
tients with oral GVHD or Fanconi’s anemia. At
each visit, it is important to check for a history of xe-
rostomia and high-risk habits and to perform
a through oral, head, and neck and dental exam.
Appropriate dental and radiologic assessment for
tooth development should be performed in
children.RESPIRATORY COMPLICATIONS
Late pulmonary complications amongHCT recip-
ients include idiopathic pneumonia syndrome, bron-
chiolitis obliterans syndrome (BOS), cryptogenic
organizing pneumonia (COP), and sinopulmonary in-
fections [28]. Allogeneic HCT recipients have higher
risks than autologous HCT recipients. Predisposing
factors can include infections, extent, and type of pre-
transplantation and conditioning regimen chemother-
apy and radiation exposure, and GVHD. Pulmonary
complications can be associated with significant mor-
bidity and mortality.
Idiopathic pneumonia syndrome, also known as
interstitial pneumonitis, more commonly presents in
the early posttransplantation period. However, it can
occur in long-term survivors and can lead to late respi-
ratory impairment. Predisposing factors include allo-
geneic HCT, exposure to high-dose TBI, and
GVHD. Immune compromise delays recovery from
infection, allowing greater damage to the lung intersti-
tium. Certain chemotherapeutic agents (eg, BCNU,
bleomycin, busulfan, methotrexate) can cause lung
toxicity directly or can enhance the damaging effects
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shielding can decrease radiation toxicity. Prophylaxis
strategies focus on decreasing the risks of infections
post-HCT, especially among patients with cGVHD.
BOS occurs in 2% to 14% of allogeneic HCT
recipients and is almost exclusively seen among pa-
tients with cGVHD; some experts classify BOS as pul-
monary GVHD [29-31]. BOS may develop in patients
with no other clinical manifestations of GVHD. BOS
is characterized by the new onset of an obstructive lung
defect and clinically manifests as dyspnea on exertion,
cough, or wheezing. Patients may be asymptomatic
early in the disease process. BOS is clinically
diagnosed when all of the following criteria are met
together with active cGVHD in at least one organ
other than the lung: (1) forced expiratory volume in
1 second (FEV1)/forced vital capacity ratio\ 0.7 and
FEV1 \ 75% of predicted; (2) evidence of air
trapping or small airway thickening or bronchiectasis
on high-resolution chest computed tomography,
residual volume .120%, or pathologic confirmation
of constrictive bronchiolitis; and (3) absence of
infection in the respiratory tract, documented with
investigations (eg, bronchoalveolar lavage) directed
by clinical symptoms. Some experts consider
a decrease in the FEV1 of 10% or greater from
pretransplantation baseline as a diagnostic criterion
for BOS or an indication for more frequent follow-
up pulmonary function test (PFT) assessments. The
value of using spirometry to screen for BOS in the ab-
sence of symptoms is not well defined. Treatment of
BOS includes immunosuppressive agents such as cor-
ticosteroids, calcineurin inhibitors, sirolimus, and an-
tithymocyte globulin. The prognosis of BOS is poor,
and 5-year survival rates are\20% if patients do not
respond to initial treatment [30,31].
COP, previously known as bronchiolitis obliterans
organizing pneumonia, is a clinicopathologic syndrome
that involves the bronchioles, alveolar ducts, and the al-
veoli, and is the result of a variety of toxic, immuno-
logic, or inflammatory injuries to the lungs. COP
presents typically in the first 6 to 12 months posttrans-
plantation, although later onsetmayoccur, especially in
patients with cGVHD. Clinical presentation includes
nonproductive cough, low-grade fevers, and dyspnea.
Radiologic imaging may reveal patchy consolidation
with ground glass or nodular infiltrates. Pulmonary
function tests typically show a restrictive pattern. Bi-
opsy may be needed to confirm the diagnosis of COP.
Mainstay of treatment is corticosteroids, and 80% of
patients can be expected to recover, but relapses are
common if steroids are rapidly tapered. This complica-
tion is rare after transplantation, and no specific screen-
ing tests are available for early diagnosis and
prevention.
Recurrent sinopulmonary infections can occur in
patients with delayed immune reconstitution andcGVHD (see section on Immunity and Infections).
Appropriate vaccination is recommended, and in pa-
tients with ongoing immune deficiency and infections,
monitoring of immune globulin levels should be con-
sidered with targeted replacement as recommended
elsewhere in these guidelines.
Other rare late complications involving the lungs
include diffuse alveolar hemorrhage, pulmonary
thromboembolism, pulmonary veno-occlusive disease,
and pleural effusions.
Recommendations
1. Routine clinical assessment by history and physical
exam for pulmonary complications is recommen-
ded for all patients at 6 months, 1 year, and yearly
thereafter.
2. Some experts recommend earlier and more fre-
quent clinical assessments including PFTs in pa-
tients with cGVHD.
3. History of smoking should be assessed, and patients
who smoke or are at risk for passive smoking should
be counseled regarding smoking cessation.
4. In patients with symptoms or signs of lung compro-
mise, PFTs and focused radiologic assessment
should be performed as clinically indicated.
Follow-up evaluations should be guided by clinical
circumstances for patients with recognized defects.CARDIAC ANDVASCULAR COMPLICATIONS
In comparison to other complications, clinically
evident cardiac and cardiovascular complications after
HCT are rare. Cardiac toxicity accounts for late deaths
in 2% of autologous and 3% of allogeneic HCT recip-
ients. However, it is likely that cardiac and vascular
complications are still underestimated. Experiences
of cancer survivorship in the nontransplantation set-
ting may provide an estimate of the magnitude of
risk in HCT recipients. In a cohort of 1,474 long-
term survivors with Hodgkin lymphoma (among
whom 84% received mediastinal radiation), the risk
of cardiac and cardiovascular diseases was three to
five times increased compared with a general popula-
tion [32]. Therefore, cardiac and cardiovascular com-
plications may increase with longer follow-up after
HCT.
Late cardiac events can appear years and even de-
cades after HCT and may manifest as subclinical ab-
normalities or present as overt congestive heart
failure or angina. The cardiac complications include
any cardiac dysfunction because of cardiomyopathy,
valvular anomaly, or conduction anomaly. Many fac-
tors are involved, such as the cumulative exposure to
anthracyclines and chest radiation before HCT, car-
diac function before transplantation, intensity and
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transplantation factors. Previous use of cardiotoxic
chemotherapy and chest radiation plays a major role.
For patients with nonmalignant diseases such as hemo-
globinopathy or aplastic anemia, transfusion history
and the resultant iron overload may be important.
With advancing age at the time of HCT, common pre-
existing cardiac diseases may be increased. Assessment
before transplantation for all HCT recipients should
include inquiry about exposure to pretransplantation
chemotherapy (eg, cumulative dose of anthracyclines)
and chest and neck radiation therapy and evaluation
of preexisting cardiac and cardiovascular disease.
Anthracycline cardiomyopathy is characterized by
a dose-dependent progressive decrease in systolic left
ventricular function. At total doses of \400 mg/m2
body surface area, the incidence of congestive heart
failure is 0.14%; this incidence increases to 7% at
a dose of 550 mg/m2 and to 18% at a dose of 700
mg/m2. Mediastinal radiotherapy applied before
HCT can cause a variety of cardiac complications by
producing inflammation and fibrosis of all structures
of the heart. Restrictive cardiomyopathy, fibrosis of
the electrical conduction pathways with arrhythmias,
and autonomic dysfunction, as well valvular defects,
with left-sided valve regurgitation and valve thickening
are the deleterious consequences.
Cardiovascular disease involves changes of the
whole arterial vascular network and can include cere-
brovascular disease, ischemic heart disease, and
peripheral arterial disease after HCT. These cardio-
vascular events may have diverse clinical manifesta-
tions, such as stroke, transient ischemic attack,
myocardial infarction, angina pectoris, chronic coro-
nary artery disease, ischemic leg pain, or gangrene.
In a retrospective single-center study, the cumula-
tive incidence of a cardiovascular complication was
22% at 25 years after allogeneic HCT [33]. The rela-
tive risk of developing a late arterial event was sign-
ificantly higher after allogeneic than after autologous
HCT, supporting the hypothesis that the allo-
reaction may be involved in the atherosclerotic pro-
cess. The established cardiovascular risk factors
(hypertension, dyslipidemia, diabetes, smoking, physi-
cal inactivity) were associated with higher risks of car-
diovascular complications posttransplantation. Some
conditioning regimens may have inherent cardiac
toxicity with long-term cardiac consequences [34].
A high prevalence of metabolic syndrome, elevated
triglycerides, elevated blood pressure, abdominal obe-
sity, and diabetes has been reported among allogeneic
HCT survivors, even when off immunosuppressive
treatment. Prolonged and intensified immunosuppres-
sive treatment, posttransplantation endocrine dysfunc-
tion, and insulin and/or leptin resistance could be
some of the possible causes. Although studies support-
ing evidence-based guidelines are lacking in HCT,prevention and early treatment of the cardiovascular
risk factors may decrease the risk of late cardiovascular
complications after HCT [35].
Recommendations
1. Routine clinical assessment and cardiovascular risk
factor evaluation for all HCT recipients at 1 year
and yearly thereafter. More frequent assessments
and if clinically appropriate, extended cardiac eval-
uations (eg, electrocardiogram, echocardiogram)
may be indicated in patients at high risk for
cardiac complications (eg, patients with Hodgkin
lymphoma who have received mediastinal radia-
tion therapy, patients with amyloidosis, and pa-
tients with preexisting cardiac and vascular
abnormalities).
2. Education and counseling on ‘‘heart-healthy’’ life-
style (regular exercise, maintaining healthy weight,
no smoking, dietary counseling) for all HCT
recipients (see section on General Screening and
Preventive Health).
3. Appropriate treatment of cardiovascular risk factors
such as diabetes, hypertension, and dyslipidemia for
all HCT recipients. Among patients started on drug
therapy for dyslipidemia, follow-up assessments
should be performed based on published guidelines
(fasting lipid panel every 6-8 weeks until treatment
goal is achieved and then every 4-6 months) [36].
4. Endocarditis prophylaxis in HCT recipients
according to the recommendations of the American
Heart Association [15].LIVER COMPLICATIONS
Late liver complications are most commonly re-
lated to medications, cGVHD, hepatitis B or C virus
(HCV), or iron overload [37]. The etiology of liver
dysfunction may be multifactorial, and a careful his-
tory, physical examination, and review of medications
can often provide clues. In addition, the time course of
onset and pattern of liver function test (LFT) abnor-
malities, history of pretransplantation hepatitis, diag-
nosis of GVHD at other sites, and number of blood
transfusions pre- and posttransplantation can be useful
in determining the etiology of liver disease.
Chronic GVHD is a major cause of liver dysfunc-
tion after transplantation and can manifest with ele-
vations of serum alanine transaminase, alkaline
phosphatase, and gamma glutamyl transferase. Evalu-
ation should exclude other causes of liver dysfunction
(eg, viral infections, drug injury). Liver biopsy should
be performed to confirm the diagnosis when liver dys-
function occurs as the only manifestation of cGVHD
and systemic immunosuppression is being considered.
Immunosuppressive therapy is indicated for liver
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junct. Liver transplantation has successfully been
performed in several rare cases of progressive liver
failure [38].
Long-term survivors with hepatitis B generally
have mild to moderate liver disease. Chronic HCV in-
fection is often asymptomatic with fluctuating trans-
aminase levels as the only manifestation during the
first decade following transplantation. However, the
cumulative incidence of HCV progressing to cirrhosis
is 11% at 15 years and 24% at 20 years, being more
rapid in transplantation than nontransplantation pa-
tients (18 versus 40 years) [39]. Extrahepatic HCV
disease and genotype 3 are associated with progres-
sion to cirrhosis. In patients with known HCV infec-
tion, liver biopsy can be considered at 8 to 10 years
after transplantation to assess for the presence of
cirrhosis.
HCT recipients are at risk of developing iron over-
load primarily from red blood cell (RBC) transfusions
as part of their supportive care both pre- and post-
transplantation, although increased iron absorption
because of ineffective erythropoiesis and a carrier state
for hereditary hemochromatosis, if present, may also
contribute [40]. Iron overload in late survivors has
been associated with increased infections and may
mimic hepatic cGVHD. Although serum ferritin is
a sensitive test for iron load, as an acute phase reactant,
it is not a specific test. When iron overload is sus-
pected, the hepatic iron content should be estimated
by appropriate imaging (specialized magnetic reso-
nance imaging [MRI] protocols or superconducting
quantum interference device [SQUID]) or liver bi-
opsy. MRI and SQUID are noninvasive tests and
have been shown to be sensitive and specific for quan-
tifying liver iron content. These are the preferred
methods unless a tissue sample is needed to assess for
other potential etiologies of liver dysfunction. Survi-
vors with mild iron overload may not require any ther-
apy, as there are reports of iron load decreasing with
time, but they should be counseled to avoid iron sup-
plements and alcohol ingestion. Although more data
are needed to determine the incidence of end-organ
damage from iron overload, patients with significant
iron overload (eg, .7 mg/g dry weight liver iron)
and liver dysfunction are candidates for phlebotomy
or iron-chelation therapy. Iron-chelation therapy be-
fore or early posttransplantation is being investigated
in patients with pretransplantation iron overload.
Among patients who are at risk for iron overload and
require vitamin supplementation, iron-free prepara-
tions should be considered.
HCT recipients who have thalassemia or have
been heavily transfused pretransplantation (eg, other
hemoglobinopathies and bone marrow failure syn-
dromes) are particularly at risk for iron overload and
acquired hepatitis B virus and HCV infections.Recommendations
1. LFTs (total bilirubin, alkaline phosphatase, and
transaminases) should be performed every 3 to 6
months for the first year and then at least yearly
thereafter. More frequent assessments may be
needed based on an individual patient’s medical sta-
tus (eg, patients with GVHD) and particularly in al-
logeneic transplantation survivors.
2. Patients with hepatitis B and HCV should have vi-
ral load monitored by polymerase chain reaction,
and consultation with liver and infectious disease
specialists for antiviral therapy is advised. Liver spe-
cialists may recommend a liver biopsy in patients
with chronic HCV infection to determine the ex-
tent of cirrhosis. This is particularly important in
patients 8 to 10 years posttransplantation
3. Serum ferritin should be measured at 1 year post-
transplantation in patients who received RBC infu-
sions pre- or posttransplantation. Subsequent
monitoring with serum ferritin should be consid-
ered among patients with elevated levels, especially
in the presence of abnormal LTFs, continued RBC
transfusions, or HCV infection. Additional diag-
nostic testing (eg, liver biopsy, MRI or SQUID)
may be indicated if therapy is contemplated for sus-
pected iron overload.RENAL AND GENITOURINARY
COMPLICATIONS
Renal dysfunction among HCT survivors can be
caused by a number of exposures in the pre-, peri-,
and posttransplantation period. The incidence of
chronic kidney disease (CKD), defined as sustained de-
crease in glomerular filtration rate below 60 mL/min/
1.73 m2, has been reported to range from 5% to 65%
[41,42]. CKD usually becomes apparent 6 to 12
months after transplantation, although it can occur
earlier as well as much later posttransplantation.
Renal dysfunction may present as thrombotic
microangiopathy, glomerulonephritis, or nephrotic
syndrome, and radiation nephritis may occur after
exposure to TBI. The majority of patients have an
idiopathic form of CKD, which is not associated
with thrombotic microangiopathy or nephrotic
syndrome and has a multifactorial etiology.
Risk factors for CKD in long-term survivors of
HCT include older age at HCT, diagnosis (eg, mye-
loma) and pretransplantation renal function and ther-
apy exposures (eg, platinum compounds), acute
GVHD and cGVHD, use of TBI in conditioning reg-
imen, exposure to medications to prevent or treat
GVHD (eg, calcineurin inhibitors), and certain anti-
microbials (eg, acyclovir, amphotericin B, aminogly-
coside antibiotics) [42,43]. Antibiotics and antifungal
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Calcineurin inhibitors can cause glomerular
thrombosis and tubular injury. A long-term syndrome
of calcineurin inhibitor-associated renal injury can af-
fect both renal arterioles and tubules and can be ac-
companied by interstitial fibrosis. CMV infection has
also been associated with glomerular injury, and the
use of foscarnet for CMV infection can further induce
tubulointerstitial nephritis and irreversible damage be-
cause of crystallization within the renal tubules. Radi-
ation exposure (eg, TBI) can lead to degeneration and
sclerosis of arterioles and secondary destruction of glo-
meruli and tubules.
Patients with substantial hemorrhagic cystitis in the
early posttransplantation period experience a greater
risk of later bladderwall scarring and contraction. Eval-
uation and treatment of polyoma or adenoviruses may
be warranted in some patients with hemorrhagic cysti-
tis, especially if they have received an extended duration
of immunosuppressive therapy. Patients receiving im-
munosuppressive therapy for cGVHD, particularly
women with GVHD of the vulva and vagina are at
risk of recurrent urinary tract infections.
Recommendations regarding complications of the
genital and reproductive organs are also addressed in
the Endocrine Complications and Mucocutaneous
Complications sections.
Recommendations
1. Blood pressure should be checked at every clinic
visit, and hypertension should be investigated and
managed appropriately in all HCT recipients (see
section on General Screening and Preventive
Health).
2. Renal function should be evaluated at 6 months, 1
year, and at least yearly thereafter for all HCT re-
cipients. Screening should include assessment of
BUN, creatinine, and urine protein. Further
workup (eg, renal ultrasound, renal biopsy), as clin-
ically indicated should be pursued in patients with
late-onset acute renal failure or CKD posttrans-
plantation. More frequent assessments may be
needed based on an individual patient’s medical
status (eg, ongoing therapy with calcineurin
inhibitors).
3. In patients with progressive CKD, avoid nephro-
toxins and consider early referral to a nephrologist
for evaluation and treatment.COMPLICATIONS OF MUSCLE AND
CONNECTIVE TISSUE
Major late complications affecting muscle and
connective tissue after HCT include steroid-induced
myopathy, fasciitis/scleroderma, and polymyositis.One case-matched control study reported that 35%
of 10-year survivors afterHSCT still complain of mus-
culoskeletal stiffness, cramps, weakness, and joint
swelling, and the incidence of musculoskeletal prob-
lems was significantly higher than controls [44]. Possi-
ble causes of these problems may include sedentary
lifestyle combined with muscle loss, myopathy, or fi-
bromyalgia related to steroid treatment, or sclero-
derma/fasciitis related to cGVHD.
Myopathy after HCT is one of the most frequent
complications of long-term steroid therapy for
cGVHD. It is associated with moderate to severe func-
tional impairment and may also be associated with an
increased risk of mortality. Proximal lower extremity
muscles are commonly involved, with the quadriceps
muscle being most severely affected. The myopathy
progresses insidiously in most cases. Clinical observa-
tion of a patient changing position from supine to sit-
ting or sitting to standing may reveal early myopathy.
The use of a questionnaire such as the Human Activity
Profile may lead to its early detection [45]. Posttrans-
plantation fatigue contributes to inactivity, which ex-
acerbates muscle atrophy. Therefore, it is also
important to encourage progressively increasing phys-
ical activity to stop this vicious cycle.
Myositis or polymyositis is a distinctive feature of
cGVHD as defined by National Institutes of Health
consensus criteria [29]. Although the incidence of
myositis in patients with cGVHD is much higher
than in the general population, it is a rare complication
after HCT. Chronic GVHD-associated polymyositis
or myopathy usually occurs 2 to 5 years after HCT,
and the common presenting symptoms are moderate
to severe proximal muscle weakness and/or myalgia.
Lower extremities are more commonly involved.
This syndrome may be hard to distinguish from ste-
roid-induced myopathy. The majority of patients
have elevated serum creatinine kinase (CK) levels,
a myopathic pattern on electromyography, a largely
perifascicular lymphocytic infiltration on muscle bi-
opsy, and a very favorable response to immunosup-
pressive therapy [46]. It is often a challenge to
differentiate the muscular weakness of cGVHD-
associated myositis or myopathy from that of steroid
myopathy/peripheral neuropathy, as a few patients
with cGVHD-associated myopathy have a normal
CK level and lack lymphocytic infiltration in the mus-
cle biopsy.
Sclerosis can affect the skin and subcutaneous tis-
sues including fasciae, joints, and the musculoskeletal
system with varying degrees of severity and is a diag-
nostic feature of cGVHD. Early involvement of fasciae
and tendons is associated with edema and an eosino-
philic infiltrate, with later progression to fibrosis and
joint contractures, most commonly in fingers, wrists,
shoulders, elbows, and ankles. Inflammation of the
synovium may produce joint effusion. As sclerosis
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Aggressive and prolonged immunosuppressive therapy
is necessary to prevent progression of contractures, but
it is usually ineffective at reversing established contrac-
tures. Early intervention and rehabilitation become es-
sential to restore range of motion and strength.
Stretching exercises and myofascial massage are im-
portant to help improve the range of motion of af-
fected joints and to restore functions of daily living
[18]. Regular survey of range of motion at all target
joints by clinicians as well as patients is also essential
to detect early and potentially reversible limitation of
movement.
The presence of a variety of autoantibodies such as
antismooth muscle, antinuclear, and antimitochon-
drial antibodies after HCT has been observed, but in
most cases, they are not associated with any clinical
symptoms.However, in rare cases, donor-derived anti-
acetylcholine receptor antibodies may be present with
clinical manifestations of myasthenia gravis [47].
Adoptive transfer of abnormal lymphocyte clones has
been suggested as a possible mechanism, but immune
dysregulation associated with concomitant cGVHD
might be a contributing factor.
Recommendations
1. All HCT recipients should follow general popula-
tion age-specific guidelines for physical activity
(See section on General Screening and Preventive
Health).
2. For patients on corticosteroids, frequent clinical
evaluation is recommended for steroid-induced
myopathy by manual muscle tests or by assessing
patients’ ability to go from a sitting to a standing
position.
3. Patients with muscle weakness, myalgias, or ar-
thralgias should be evaluated for possible cGVHD
or steroid-associated myositis and other muscular
disorders (eg, myasthenia gravis).
4. Among patients with cGVHD, joint range of mo-
tion should be evaluated to detect sclerotic changes.
Patients should also be instructed to perform self-
assessment of range of motion.
5. Where prolonged corticosteroid exposure is antic-
ipated or when fasciitis or scleroderma develops,
a physical therapy consultation should be consid-
ered to establish baseline function and provide
range of motion andmuscle strengthening exercises
to minimize loss of function.SKELETAL COMPLICATIONS
Bone density loss is a well-recognized complica-
tion of HCT. There is a wide variation in the reported
incidence of this complication; some studies have re-
ported incidence rates as high as 25% for osteoporosisand 50% for osteopenia [48-51]. Rapid loss of bone
usually takes place within 6 to 12 months after
transplantation. Certain patients are more susceptible
to bone loss including elderly, women, patients with
low body weight (body mass index\20 to 25 kg/m2),
patients who are physically inactive, and patients who
receive extended corticosteroid therapy for their
underlying disease before transplantation or for
GVHD after transplantation. Some experts consider
prolonged corticosteroid exposure as use of $5 mg
prednisone equivalent daily for .3 months [52]. Pro-
viders should also consider corticosteroid exposure
pretransplantation when determining risk for bone
loss (eg, as part of treatment regimens for lymphoma
and acute lymphoblastic leukemia). The use of calci-
neurin inhibitors and other immunosuppressive ther-
apy may increase the risk for this complication.
Studies suggest that both the total cumulative dose
and the duration of corticosteroid therapy are impor-
tant factors for the development of osteopenia [48].
Other possible contributing factors include hypogo-
nadism, secondary hyperparathyroidism because of the
decrease in serum levels of calcium and vitamin D,
and direct toxicity from conditioning to bone cells
and bone marrow stromal cells. Standard preventive
measures include adequate physical activity in the
posttransplantation period, use of supplemental cal-
cium and vitamin D, and consideration of estrogen re-
placement therapy in deficient women.
Dual photon densitometry is currently the best
tool to assess the degree of bone loss. Osteopenia
and osteoporosis are differentiated by the degree of re-
duction in bone mass and can be quantified by T and Z
scores by dual photon densitometry. Normal values of
bone density have not been well established in chil-
dren, although it is clear that the loss of bone density
and increased risk of fracture is a significant issue in
children after HCT. The femur neck and lumbar spine
are the two most frequently measured sites by bone
densitometry. Studies have shown differential effects
in the extent and length of post-HCT bone density
loss. Bone loss is more severe, persistent, and resistant
to therapy in cortical bones such as the femur neck
than in trabecular bones such as the spine.
Treatment choices for patients with established os-
teopenia and osteoporosis include active exercise, cal-
cium and vitamin D supplementation, use of estrogen
replacement in women, andminimizing the total expo-
sure and duration of steroid and other immune-
suppressive therapy, if possible [48]. Bisphosphonate
therapy should be considered for treatment of patients
with established osteopenia and osteoporosis, patients
with evidence of progressive bone density loss, and pa-
tients at high risk for bone loss (eg, patients with
GVHD on extended steroid therapy). The optimal
schedule and duration of bisphosphonate therapy in
HCT is not well established. Bisphosphonate therapy
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vitamin D supplementation as a preventive measure
for patients at high risk for osteopenia and osteoporo-
sis, although the data for this intervention are less
clear. Osteonecrosis of the jaw has been reported in
patients receiving bisphosphonates for osteoporosis,
especially among those undergoing oral procedures
while on these agents [53]. If appropriate, dental
evaluation should be performed before starting bi-
sphosphonates in order to detect and correct any den-
tal problems. Long-term use of bisphosphonates may
be associated with subtrochanteric fractures of the fe-
mur; extended duration of therapy with these agents
should be carefully considered until more information
about this association becomes available [54].
Avascular necrosis (AVN) has been described in
4% to 19% of HCT survivors. In addition to the risk
factors for post-HCT bone loss, inflammatory
microvascular changes related to GVHD or other
factors may contribute to this complication [55,56].
TBI has been associated with a higher incidence of
AVN in some reports. Joint pain or discomfort is
usually the first manifestation of AVN, and standard
radiographic evaluation may not detect abnormalities
until late in the disease course. Joint symptoms in
patients at risk should prompt MRI for early
detection. Although the hip is the most frequently
affected joint (over 80% of cases; bilateral in more
than 60%), other joints can be affected, including the
knees, wrists, and ankles. Symptomatic relief of
pain and orthopedic measures to decrease pressure
on the joint can be helpful. Most adult patients
with advanced AVN will require surgical
intervention. Orthopedic procedures including core
decompression in early cases and joint replacement
provide a satisfactory outcome in most patients.
However, long-term follow-up of these procedures is
needed in younger patients with a long life expectancy.
Recommendations
1. A screening dual photon densitometry should be
performed at 1 year after transplantation in adult
women, all allogeneic HCT recipients, and patients
who are at high risk for bone loss after transplanta-
tion (eg, prolonged treatment with corticosteroids
or calcineurin inhibitors). Repeat densitometry
should be performed in those with recognized de-
fects, ongoing risk factors, or to follow-up response
to therapy. Physicians should evaluate gonadal and
other related endocrine abnormalities in patients
with decline in bone density.
2. Patients should be counseled about preventivemea-
sures for bone loss and fractures such as physical ex-
ercise, fall prevention, and vitamin D and calcium
supplementation. Hormone replacement therapy
should be discussed with women who have estrogendeficiency. Some experts recommend the use of bi-
sphosphonates for patients at high risk for bone loss.
3. Screening for AVN is not recommended; however,
clinicians should maintain a high level of suspicion
for patients with exposure to irradiation or pro-
longed corticosteroids and evaluate patients with
joint symptoms promptly.CENTRAL AND PERIPHERAL NERVOUS
SYSTEM COMPLICATIONS
Neurologic complications after HCT may affect
the central and peripheral nervous system and are
mostly secondary to infections, drug-elated toxicity,
and metabolic encephalopathy. The effect on cogni-
tive function and level of alertness can be subclinical
with white matter changes detected up to a year later.
The reported complication rate is higher in allogeneic,
especially alternative donor HCT, compared with au-
tologous HCT recipients [57,58].
Complications include central nervous system in-
fections in immunocompromised recipients and vascu-
lar complications such as stroke and calcineurin
inhibitor-induced neurotoxicity. Leukoencephalop-
athy may occur as sequela of intrathecal chemotherapy
and cranial irradiation. Patients who have received
TBI or cranial irradiation are at increased risk of
secondary solid tumors of the brain on long-term
follow-up. Children exposed to TBI are also at risk
for developmental delays. There is growing evidence
of a GVHD effect on the central nervous system. A ce-
rebral angiitis-like syndrome has been described with
cerebral ischemic lesions and leukoencephalopathy
secondary to GVHD. Guillain-Barre – like syndrome
with peripheral neuropathy and chronic demyelinating
polyneuropathy related to GVHD has been reported
[47,59,60]. Peripheral neuropathy after HCT may be
related to chemotherapy exposure.
Neuropsychologic deficits have been described in
nearly 20% of recipients and cognitive deficits in ap-
proximately 10% of HCT recipients. Patients with
a history of central nervous system disease (eg, adeno-
sine deaminase deficiency-associated severe combined
immunodeficiency) and children treated with cranial
radiation alone or in combination with chemotherapy
are at higher risk. Cognitive changes may be subtle and
difficult to detect, making it imperative for the clini-
cian to be vigilant even in patients who do not have
any specific complaints [59,61]. Neurocognitive
function generally improves over time, but long-term
deficits can remain in more than 40% of survivors [62].
Recommendations
1. All HCT recipients should undergo clinical assess-
ment for symptoms or signs of neurologic
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thereafter. Earlier and more frequent evaluations
may be considered in high-risk patients (eg, alloge-
neic HCT recipients, patients receiving prolonged
immune suppression with calcineurin inhibitors,
patients receiving TBI, cranial radiation, or
intrathecal chemotherapy, and patients with
cGVHD).
2. Evaluation for cognitive developmental milestones
should be performed at least annually in pediatric
patients. Adult patients should be queried annually
for changes in cognitive function, which may be
subtle.
3. Further evaluation (eg, MRI, nerve conduction
studies, electromyography, neuropsychiatry test-
ing) may be warranted in recipients with symptoms
or signs of neurologic or cognitive dysfunction.ENDOCRINE COMPLICATIONS
Chemotherapy, radiation therapy, and HCT can
all result in impairment of endocrine function. The
most significant endocrine complications are associ-
ated with exposure to radiation and chemotherapeutic
agents (eg, busulfan), cGVHD, and prolonged cortico-
steroid exposure [63].
Subclinical, compensated hypothyroidism, with
elevated TSH and normal serum-free T4 levels, oc-
curs in 7% to 15% of patients in the first year after
transplantation. The reported incidence of frank hy-
pothyroidism is variable depending on risk factors
in the population studied. Single-dose ablative TBI
is associated with a 50% incidence of overt hypothy-
roidism, whereas fractionated TBI is associated with
an incidence of about 15%. The incidence reported
after busulfan and cyclophosphamide conditioning
is 11%. Treatments given before transplantation
likely also contribute to the risk of thyroid abnormal-
ities. The median time to diagnosis of hypothyroid-
ism is nearly 4 years after HCT or TBI exposure.
When TSH is elevated with normal T4 levels, assess-
ment should be repeated in 2 months, or therapy
should be initiated at the discretion of the treating
physician. Patients who start thyroid hormone
replacement should be reassessed at about 6 weeks af-
ter initiation of therapy. Further individual dose ad-
justment should be based on periodic thyroid
assessment, most often recommended at 6-month in-
tervals. Autoimmune thyroiditis may also occur fol-
lowing radiation. Radiation to the neck and TBI
has been associated with dose-related increases in
risk of thyroid malignancy, often with long latent
periods [64].
Gonadal dysfunction is highly prevalent in HCT
recipients, with rates as high as 92% for males and
99% for females. The degree of dysfunction dependson age, gender, pretransplantation therapy, and condi-
tioning regimen [65]. Although the risk of gonadal fail-
ure is high in all individuals, women generally
experience higher rates of failure than do men.
Women are at high risk of hypergonadotropic hy-
pogonadism after HCT [66]. Hypogonadism is nearly
universal after high-dose irradiation or busulfan. The
risk is lower with cyclophosphamide alone. In general,
ovarian endocrine failure is irreversible in adult women,
but younger women, particularly prepubescent girls,
have a better opportunity for recovery of gonadal
function.
Fractionation of radiation reduces the risk com-
pared with unfractionated radiation. Prepubertal girls
should be monitored closely for onset of puberty
and, if puberty is not experienced by age 12 to 13, be
referred for full endocrinology evaluation and consid-
eration of hormone supplementation. Adult women
should be evaluated by a gynecologist and may require
hormone replacement therapy to maintain libido, sex-
ual function, and bone density. Libido is often de-
creased and only partially corrected by hormone
replacement therapy in women. Vaginal GVHD may
result in strictures and synechiae. Supplemental vagi-
nal lubrication is available and should be discussed
by the treating physician.
Most men have normal testosterone levels after
transplantation, although germ cell damage (infertil-
ity) is a near-universal finding in men exposed to
high doses of radiation or chemotherapy. Most reports
suggest that prepubertal boys experience normal pu-
berty and demonstrate normal testosterone levels
following HCT [66]. Testing and consideration of
hormone replacement therapy for men is recommen-
ded based on symptoms. Failure to progress through
puberty in a timely fashion should prompt referral
for a full endocrinology evaluation.
Transplantation recipients have a low incidence of
primary adrenal failure after HCT. Chronic therapy
with corticosteroids for GVHD will suppress the
pituitary-adrenal axis, but function usually recovers
gradually once exogenous corticosteroid exposure
ends. Greater length and intensity of exposure is gen-
erally associated with longer persistence of adrenal
suppression. Patients with prolonged exposure to cor-
ticosteroids after HCT should have adrenal axis test-
ing when withdrawing corticosteroids, particularly if
symptoms of adrenal insufficiency develop. Clinicians
should maintain awareness of possible hypoadrenalism
in patients receiving long-term corticosteroids who
develop acute illness and consider ‘‘stress-dose’’
corticosteroids.
Growth in children may be adversely affected by
HCT, depending on their pretransplantation therapy
and conditioning regimen [65,66]. A large body
of data suggests that radiation is associated with
growth defects in children who receive HCT.
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diminished growth in children. Some reports suggest
that chemotherapy alone may cause growth
deficiencies. Growth is a complicated process and
may be adversely affected by many additional factors,
including general illness, nutritional deficits,
hormonal deficiencies, long-term corticosteroids, and
GVHD. The risk of impaired growth is greatest in
the youngest children. Children should be closely
monitored for appropriate growth velocity after
HCT. A pediatric endocrinologist should evaluate
children who do not achieve adequate growth, and as-
sessment of growth hormone levels should be consid-
ered. Growth hormone deficiency following TBI has
been shown in some studies but not in others. Because
growth failure is likely to be multifactorial, consider-
ation must be given to causes other than inadequate
growth hormone. The benefits of growth hormone
supplementation are unclear. However, in children
with demonstrated deficiency, supplementation is
commonly prescribed.Recommendations
1. Thyroid function tests (TSH, T3, and free T4)
should be performed at 1 year and yearly thereafter
in all transplantation recipients and additionally if
relevant symptoms develop.
2. Clinical and endocrinologic gonadal assessment at
1 year after HCT is recommended for all women
who were postpubertal at the time of transplanta-
tion. Frequency of subsequent assessments should
be guided by clinical need (eg, menopausal status).
Women should have annual gynecologic evaluation
as part of general health screening, at which time,
hormone replacement therapy should be addressed
for those who are postmenopausal.
3. Gonadal function in men, particularly FSH, LH,
and testosterone, should be assessed if symptoms
warrant (lack of libido or erectile dysfunction).
Consider referral to an endocrinologist for men
who may need testosterone replacement therapy.
4. Clinical and endocrinologic gonadal assessment of
prepubertal boys and girls should be initiated 6 to
12 months after transplantation, with further
follow-up schedule determined in consultation
with an endocrinologist.
5. Patients withdrawing from prolonged corticoste-
roid usage should have slow terminal tapering of
corticosteroids; stress doses of corticosteroids may
be warranted during acute illness in patients who
have been on chronic corticosteroids in the past.
6. Growth velocity should be monitored every year
in all children, with assessment of thyroid
function and growth hormone if growth velocity
is abnormal.MUCOCUTANEOUS COMPLICATIONS
Late complications involving skin and appendages
are frequent after HCT [67]. Nearly 70% of patients
with cGVHD experience skin involvement. Early
changes of lichen planus-like or papulosquamous le-
sions may progress to sclerosis or poikiloderma and
can be associated with skin ulcers and subsequent in-
fections. Alopecia, thinning of scalp hair, nail dystro-
phy, sweat impairment, and skin dyspigmentation are
common complications after cGVHD.
HCT survivors, especially recipients of allogeneic
HCT, are at risk for developing secondary cancers of
the skin [24]. Patients should be counseled about early
detection and prevention of skin cancers including
avoiding excessive sun exposure, using adequate skin
protection and periodic self-examination of the skin
with prompt referral to a dermatologist for further
evaluation and treatment of suspicious skin lesions.
Severe genital GVHD may develop in approxi-
mately 12% of women with or without associated
systemic GVHD [68,69]. Patients may present with
excoriated or ulcerated mucosa, fissures, narrowing
of introitus, or vaginal scarring and obliteration that
may lead to hematocolpos. Initial symptoms may be
mild and nonspecific such as dryness, dyspareunia, or
postcoital bleeding, and if not recognized, they may
lead to important sexual dysfunction. Careful
questioning and examination should be performed, as
patients without sexual activity may not detect these
abnormalities, and sexually active patients may not
disclose relevant symptoms. Biopsy may be needed
to establish the diagnosis. Care should be taken
when reducing systemic immunosuppression, as
reactivation of genital GVHD may occur. Vaginal
strictures may limit the performance of routine
Papanicolaou smears as well as sexual intercourse.
Treatment of vaginal GVHD includes topical
steroids, topical cyclosporine, and vaginal dilators.
Surgical intervention can be used to treat severe
cases. In contrast to cGVHD, patients with
hypoestrogenism because of premature menopause
may present with thin and pale vulvar mucosa that
responds well to lubricants and topical estrogens.
However, patients may have changes because of
GVHD and hypoestrogenism concurrently. Genital
involvement with GVHD is less common in men and
may result in phimosis.Recommendations
1. Patients should perform routine self-examination
of the skin and avoid excessive exposure of sunlight
without adequate protection.
2. All female recipients of allogeneic HCT should
have clinical screening for symptoms of genital
GVHD. Women who have established cGVHD
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tal involvement.
3. Patients should be counseled about self-
examination of the vaginal area, general hygiene
measures, and early recognition of local symptoms.
Application of topical vaginal immunosuppressive
agents, such as ultrahigh-potency corticosteroids
or calcineurin inhibitors, prescription of systemic
hormonal replacement therapy if indicated, and
the use of vaginal dilatators should be initiated early
in the course of the disease.SECONDARY CANCERS
Second malignancies after HCT are a devastating
late complication. Patients receiving allogeneic HCT
have a two to three fold increased risk of developing
solid tumors, compared with an age-, gender-, and
region-adjustedpopulation [59].Nearly all cancer types
aredescribedafter allogeneic andautologous transplan-
tation, including oral cancers, as mentioned previously.
Risk factors include radiation therapy, length, and in-
tensity of immunosuppression and cGVHD[26].How-
ever, a recent long-term follow-up analysis of patients
who underwent transplantation after myeloablative
doses of busulfan and cyclophosphamide found similar
increased risk [25]. Risk increases with time after
transplantation, particularly for radiation-related ma-
lignancies. Recent analyses suggest that risk of
radiation-related (sarcoma, breast, and thyroid cancers)
and nonradiation-related (squamous cell carcinoma
linked to cGVHD) solid tumors continues to increase
beyond 10 years posttransplantation [24,26]. Children
who have received cranial irradiation are at risk for
developing brain tumors. HCT recipients with
Fanconi’s anemia are also at risk for developing
oropharyngeal cancers. Providers can consider vaccina-
tion against the human papilloma virus according to
country-specific general population recommendations
[10]. All patients should at least receive country-
specific general population recommendations for
screening for cancers. Screening for breast cancer is
recommended at an earlier age (25 years or 8 years after
radiation, whichever occurs later) but no later than age
40 among recipients of TBI or chest irradiation. Early
referral to a dermatologist should be considered in
patients with skin lesions suspicious for cancer.
Risk of secondary leukemia or myelodysplasia after
autologous HCT is also higher than anticipated, with
an overall incidence of about 4% at 7 years after trans-
plantation, with a median onset of 2.5 years (range, 3
months to 7 years) posttransplantation. Risk appears
to be increased for patients receiving prior alkylator
therapy, prolonged administration of conventional
chemotherapy, and higher doses of pretransplantation
irradiation [70].Posttransplantation lymphoproliferative disorders
(PTLD) are a rare complication of allogeneic HCT
associated with greater donor-recipient HLA dispar-
ity, T cell depletion, and GVHD [71]. Overall inci-
dence is 1% at 10 years after HCT. Although these
usually occur early (within 6 months of transplanta-
tion), PTLD is reported as late as 8 years after HCT.
The majority of PTLD are associated with Epstein-
Barr virus infection. Quantitative polymerase chain
reaction detection of Epstein-Barr virus reactivation
allows prompt initiation of anti-CD20 monoclonal
antibody therapy before development of frank
PTLD [59].
Recommendations
1. Exposure to radiation and photosensitizing effects
of many commonly used transplantation-related
medications increases the risk of skin cancers
amongHCT recipients. All HCT recipients should
be encouraged to reduce UV skin exposure through
use of high SPF sunscreens or skin coverage.
2. All patients should be advised of the risks of
secondary malignancies annually and encouraged
to routinely perform recommended screening
self-examination such as genital/testicular and
skin examination. Women should discuss breast
self-examination with their physicians. All patients
should be encouraged to avoid high-risk behaviors
as recommended under the General Health and
Preventive Screening section, including avoidance
of tobacco, passive tobacco exposure, or excessive
unprotected skin UV exposure.
3. Screening clinical assessment should be performed
yearly and should include symptom review for
secondary malignancies. Clinical examination and
screening for secondary malignancies should
follow the recommendations outlined under the
General Health and Preventive Screening section.
In women with radiation exposure (eg, TBI or radi-
ation to the chest region), initiation of screening
mammography should occur at age 25 or 8 years
after radiation, whichever occurs later, but no later
than age 40 years. Particular attention to oral ma-
lignancies should be paid to patients with previous
severe cGVHD of the oral and pharyngeal mucosa.PSYCHOSOCIAL ADJUSTMENTAND SEXUAL
COMPLICATIONS
Depressive symptoms and psychologic distress are
frequently observed in HCT survivors. Fatigue, anger,
insomnia, and problemswithmarital relationshipsmay
also be seen. Pediatric patients may experience altered
behavior patterns, changes in social habits, and
changes in academic/school behavior. At the transition
from acute convalescence to long-term follow-up,
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as the patient and his/her family must cope with
changes in roles, employment situations, and financial
difficulties. Spouses and other caregivers may also ex-
hibit high levels of depression and psychological dis-
tress. They often report loneliness and low levels of
perceived social support. Children may suffer from
separation from one or both parents and the conse-
quences of stress and upheaval in the family. At a min-
imum, screening for depression is recommended every
6 to 12 months after transplantation as per the general
health maintenance section (information to follow).
Specific tools for screening for psychosocial difficulties
after HCT are also available and could be used with
a similar frequency to depression screening. Sexual
dysfunction occurs in a significant number of survivors
and may be multifactorial in origin, from depression to
gonadal hormonal deficiency.
Recommendations
1. A high level of vigilance for psychological symp-
toms should be maintained. Clinical assessment is
recommended throughout the recovery period, at
6 months, at 1 year, and at least yearly thereafter,
with mental health professional assessment recom-
mended for those with recognized deficits.
2. Inquiry as to the level of spousal/caregiver psycho-
logical adjustment and family functioning should
be performed at regular intervals.
3. In adults, sexual function should be queried at 6
months, at 1 year, and yearly thereafter (see also
the section on Mucocutaneous Complications).FERTILITY
Male and female HCT survivors are at risk for
infertility secondary to pretransplantation and
transplantation-related treatment exposures [72,73].
Among transplantation survivors of the child-bearing
age group, loss of fertility can be associatedwith psycho-
logical consequences that can affect quality of life. Con-
ditioning regimens with TBI or busulfan plus
cyclophosphamide can cause gonadal failure, although
riskmay be lowerwith regimens that include cyclophos-
phamide only. Older age at transplantation and
cGVHDare associated with a low likelihood of gonadal
recovery. Nonassisted natural pregnancies following
gonadal recovery inwomen or in partners ofmale trans-
plantation recipients have been reported, but the esti-
mated incidence is\15%.
The outcome of pregnancy after transplantation is
generally good, although women are at increased risk
of fetal and maternal complications, and posttrans-
plantation pregnancy should be considered a high-
risk pregnancy [73]. The incidence of congenitalanomalies is not higher than in the normal population,
and the rate of miscarriage is not increased. Women
exposed to TBI have a higher than normal incidence
of preterm deliveries and low or very low birth weight
infants. Irradiation may result in uterine vessel damage
and reduce uterine volume.
A general recommendation is to delay spontaneous
or assisted pregnancies for at least 2 years after HCT,
because this is the period of highest risk of relapse after
transplantation. Contraception counseling in survivors
after HCT with gonadal recovery is recommended,
and contraception is advisable if fertile or if fertility
status is not known and pregnancy is not desired.
Even if the patient is infertile, barrier contraception
is recommended with new partners to prevent sexually
transmitted diseases.
Women with gonadal recovery should also be
advised about the risks of premature menopause.
Recommendations
1. Consider referral to appropriate specialists for pa-
tients who are contemplating a pregnancy or are
having difficulty conceiving.
2. Although infertility is common, patients should
be counselled regarding birth control posttrans-
plantation.GENERAL SCREENING AND PREVENTIVE
HEALTH
In addition to transplantation-specific risk factors
mentionedpreviously,HCTsurvivors face general risks
found in the population that has not undergone trans-
plantation. In general, transplantation survivors should
be under the care of physicians comfortable with
providing care for general health and hematology-
oncology specific issues. Summarized below are screen-
ing and lifestyle recommendations for the general adult
population that are also relevant for HCT survivors.
Further details about screening recommendations for
adults and children can be found at: http://www.uspre-
ventiveservicestaskforce.org [74,75].
Recommended Screening for All Patients
1. Hypertension: Blood pressure should be checked at
least every 2 years. In children, hypertension is de-
fined as readings greater than the 95th percentile
for age, sex, and height. Treatment is indicated for
readings of greater than 140/90 in adults on two sep-
arate visits at least 1 week apart, unless hypertension
is mild or can be attributed to a temporary condition
or medication (eg, cyclosporine). Nonpharmaco-
logic treatmentsmay also be tried formild hyperten-
sion and include moderate dietary sodium
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of excess alcohol intake, and regular aerobic exercise.
2. Hypercholesterolemia:Cholesterol andHDL levels
should be checked every 5 years starting at age 35 for
men and45 forwomen. Screening should start at age
20 for anyone who smokes, has diabetes, hyperten-
sion, obesity (bodymass index$30 kg/m2), or a fam-
ily history of heart disease before age 50 for male
relatives or before age 60 for female relatives. Fast-
ing is not required for accuratemeasurement of cho-
lesterol and HDL, but it is required for LDL and
triglycerides. As a rough guideline, total cholesterol
levels .200 mg/dL (.5.0 mmol/L) or HDL levels
\40 mg/dL (\1 mmol/L) should be followed up
by a full fasting lipid panel. Treatment goals are
based on overall risk of heart disease (eg, .10%
chance of coronary heart disease in 10 years). Over-
all risk assessmentwill include the following risk fac-
tors: age, sex, diabetes, clinical atherosclerotic
disease, hypertension, family history, low HDL
(\40 mg/dL or 1.0 mmol/L), and smoking. An
online calculator is available at http://www.nhlbi.
nih.gov/guidelines/cholesterol/index.htm.
3. Colorectal cancer: Screening should start at age 50
in the absence of a family history (first-degree rela-
tive diagnosed with colorectal cancer before age
60). The interval of testing depends on the type of
testing procedure and the prior screening results.
There are several screening approaches including
annual fecal occult blood testing (three cards at
home), sigmoidoscopy every 5 years with fecal oc-
cult testing every 3 years, or colonoscopy every 10
years. Virtual computerized tomography is a new
method, currently under investigation. The No. 1
approach alone or in combination has proven supe-
rior; however, a single digital rectal exam with oc-
cult blood testing is not recommended.
4. Diabetes: Screening for type 2 diabetes is indicated
for people every 3 years after age 45 or in those with
sustained higher blood pressure (.135/80) because
blood pressure targets are lower for diabetics. A
fasting plasma glucose.126 mg/dL (.7 mmol/L),
confirmed by testing on another day, is diagnostic
for diabetes.
5. Depression: Asking two simple questions about
mood and anhedonia (‘‘Over the past 2 weeks,
have you felt down, depressed, or hopeless?’’ and
‘‘Over the past 2 weeks, have you felt little interest
or pleasure in doing things?’’) is probably as effec-
tive as longer screening tools. Frequency of screen-
ing is not stated, but it is reasonable to screen every
6 to 12 months posttransplantation or as clinically
indicated. Affirmative answers to the questions
above should trigger in-depth evaluation for de-
pression to determine the need for pharmacological
or psychotherapeutic treatments.6. Sexually transmitted diseases: Chlamydia screening
is recommended for women under the age of 25
who are sexually active. Screening and appropriate
treatment decrease the incidence of pelvic inflam-
matory disease and pregnancy-related complica-
tions, although most women will be infertile after
myeloablative transplantation. Male and female
survivors should be reminded that protection
against sexually transmitted disease is important
even when pregnancy is unlikely or impossible.
SEX-SPECIFIC RECOMMENDATIONS
Recommended Screening for Men
1. Prostate cancer: There is no consensus about the
use of prostate-specific antigen or digital rectal
examination for prostate cancer screening.Recommended Screening for Women
1. Breast cancer: Screening with mammograms
should start at age 40 and occur every 1 to 2 years.
Breast self-exam is not recommended. In women
exposed to .800 cGy radiation, screening should
start at age 25 or 8 years after radiation exposure,
whichever is later but no later than age 40, based
on the data from Hodgkin lymphoma survivors.
2. Cervical cancer: Screening with pap smears should
be performed every 1 to 3 years in women older
than 21 or within 3 years of initial sexual activity,
whichever occurs earlier.
3. Osteoporosis: Screening with a bone density test
should start at age 65 for women in the general pop-
ulation or if the individual’s fracture risk is equiva-
lent to a 65-year-old woman (9.3% risk at 10 years)
[76]. An online calculator is available to determine
the 10-year risk of fracture (www.shef.ac.uk/
FRAX/). Also see the section on Skeletal Complica-
tions for additional recommendations for HCT
recipients.Healthy Lifestyle Recommendations for All
Patients
1. Eat a healthy diet with a wide variety of foods.
2. Don’t smoke (passive or active exposure), chew
tobacco, or use illegal drugs.
3. Use alcohol in moderation, generally\two drinks
per day.
4. Maintain a healthy weight.
5. Avoid excessive sun exposure and wear sunscreen
protection for anticipated periods of long exposure.
6. Follow general population age-specific guidelines
for physical activity (www.health.gov/paguidelines)
[77]. Adults (aged 18-64) should do 2 hours and 30
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and 15minutes a week of vigorous-intensity aerobic
physical activity or an equivalent combination of
moderate- and vigorous-intensity aerobic physical
activity. Aerobic activity should be performed in
episodes of at least 10 minutes. Adults should also
do muscle strengthening activities that involve all
major muscle groups performed on 2 or more
days per week.IMPLEMENTATION OF GUIDELINES IN
RESOURCE-LIMITED COUNTRIES
Although the Working Group has provided rec-
ommendations that should be applicable to all HCT
recipients, they recognized that resource constraints
may limit their implementation, especially in certain
geographic regions and developing countries. Some
examples of such challenges include the availability
of specialists with expertise and experience in manag-
ing posttransplantation complications and availability
of tests and procedures. Furthermore, issues related
to healthcare access (eg, distance to transplantation
center or healthcare facility with adequate expertise
and resources) may restrict the ability of some patients
to obtain screening and preventive care. In circum-
stances where resource limitations do not allow for
comprehensive evaluation and follow-up, healthcare
providers should use their best clinical judgment in de-
termining appropriate preventive care for HCT survi-
vors based on their individual exposures and risk
factors for long-term complications.LONG-TERM FOLLOW-UP OF HCT
RECIPIENTS
To facilitate the transition ofHCT recipients from
one phase of posttransplantation care to another,
transplantation providers should provide HCT recip-
ients with a survivorship care plan that includes a treat-
ment summary and a follow-up care plan. This
document can serve as an instrument for reminding
providers about appropriate surveillance for late com-
plications based on an individual patient’s risk factors
and exposures. Because survivors can be at risk for
late relapse, the care plan should also include appropri-
ate follow-up for the disease for which HCT was per-
formed. Survivorship care plan instruments that are
specific to HCT recipients are lacking. Until they are
routinely available, providers can consider instruments
that have been developed for cancer survivors in gen-
eral (eg, LIVESTRONG Care Plan [www.livestrong-
careplan.org], Passport for Care [www.txch.org/
passportforcare]). In addition, providers can consider
incorporating the patient version of these guidelines(available atwww.BeTheMatch.org/Patient) into a sur-
vivorship care plan document for HCT recipients.
Long-term survivors of HCT may not receive
care at their transplantation center. Because of
patient or center preference, absence of immediate
transplantation-related complications, or distance
from the transplantation center, transplantation
recipients may transition their care back to their
hematologist-oncologists, primary care physicians, or
other healthcare providers.With an increasing number
of transplantation survivors, it is likely that nontrans-
plantation healthcare providers will play a greater role
in survivorship care and may need to be aware of the
unique exposures, risk factors, and medical issues these
patients face. The working group recognized that the
models and primary site for long-term follow-up will
vary by country and available resources. On occasion,
adherence to particular recommendations may be in-
consistent with national or regional guidelines, the
availability of specific procedures or medications, or
local epidemiologic conditions. Individual clinicians
should practice best clinical judgment in implementing
these guidelines and when caring for an individual pa-
tient, should consider age, gender, coexisting comor-
bidities, cancer, and transplantation-related exposures
and immediate side effects in determining patient risks
for specific long-term complications. Prevention,
screening and management of late complications of
transplantation may require a multidisciplinary ap-
proach, with involvement of the transplantation center,
oncologists, subspecialists, primary care physicians,
and other healthcare providers, as necessary.ACKNOWLEDGMENTS
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